Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2018-12-26 Director's Dealing
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often filed via DART) to report insider holdings, changes in share ownership by directors, or major shareholders. Based on the provided categories, this aligns with 'Director's Dealing' (DIRS), which covers reports of personal share transactions or holdings by company directors and executives.
2018-12-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often referred to as the 'Insider Trading Report' or 'Director's Dealing' report) where company executives report their shareholdings and changes therein. Based on the provided categories, this aligns with 'Director's Dealing' (DIRS).
2018-12-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This is a standard regulatory filing in South Korea used to disclose insider shareholdings and transactions by company directors or major shareholders. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), as it reports the share ownership status of an executive (Yoo Won-gyu) of ABL Bio.
2018-12-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of DSC Investment in ABL Bio following an IPO. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2018-12-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by '한국투자 글로벌 제약산업 육성 사모투자전문회사' and its special related parties in '에이비엘바이오(주)'. This document type is specifically used to notify the market when a shareholder crosses a significant ownership threshold (typically 5%). In the provided classification schema, this corresponds to a Major Shareholding Notification.
2018-12-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. This falls under the category of 'Major Shareholding Notification' (MRQ) as it details the ownership status and changes in shareholding for a major shareholder (Korea Investment Global Pharma-Ecosystem Private Equity Fund) in ABL Bio.
2018-12-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.